A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs ELND 005 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Transition Therapeutics
  • Most Recent Events

    • 29 Nov 2011 New analyses focused on treatment effects at earlier stages of the disease using validated composite cognitive endpoints were presented at the 4th Conference Clinical Trials on Alzheimer's Disease, according to a Elan Corporation media release.
    • 14 Sep 2011 Results published in Neurology.
    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top